Why re-invent the wheel? Innovators around the world have already discovered and designed many compounds. Some may be very effective against SARS-CoV-2. If we could develop treatments based on these drugs, we might save valuable development time, especially if they are safe and well-tolerated.
Pharmaceutical companies, biotechs and academia have teamed up globally to bring together a library of all these antivirals and have started screening them.
Join Johan Neyts from KU Leuven and Marnix Van Loock from Janssen Pharmaceutica NV for a discussion on key learnings in the global partnership of therapeutics screening.